Wednesday, February 15, 2023 Daily Archives

Biotage to extend chromatography offering through $190m Astrea buy

by

Swedish separations company Biotage is set to acquire Astrea Bioseparations to develop its chromatography services into biologics and advanced therapeutics. Subject to closing conditions, the deal will see $190 million paid at the time of closing in shares of Biotage stock, as well as a potential $45 million to be made in milestone-based cash payments. Additionally, the acquisition will provide Gamma Biosciences (which acquired Astrea – formerly known as Prometic Bioseparations – in November 2019)  a capital injection of $25 million. The…

February 15, 2023

All eyes on CSL ahead of hemophilia B gene therapy launch

by

Other hemophilia B gene therapy developers are looking to learn from CSL as it preps to launch the $3.5 million product in the US, the firm says. In December 2022, CSL Behring won US Food and Drug Administration (FDA) approval for its one-time gene therapy Hemgenix (etranacogene dezaparvovec). The single-dose therapy treats adults with hemophilia B – a rare bleeding disorder caused by a gene defect that results in insufficient production of blood clotting protein factor IX – and has…

February 15, 2023

The final hurrah? Humira sales hits $21.2 bn in 2022

by

AbbVie expects Humira sales to fall to $13.7 billion, a 37% drop, as up to ten biosimilars are set to be available midyear. The firm reported $58 billion in total sales for 2022 with monoclonal antibody (mAb) Humira (adalimumab) contributing $21.2 billion, a 2.6% increase on the same period 2021. While the US experienced a 7.4% increase in sales annually, internationally, revenue decreased 22.2%, attributedto biosimilar competition. To date, Humira has pulled in sales of $214.2 billion for AbbVie (and previously Abbott) since…

February 15, 2023